Literature DB >> 1982326

Binding profile of SM-9018, a novel antipsychotic candidate.

T Kato1, A Hirose, Y Ohno, H Shimizu, H Tanaka, M Nakamura.   

Abstract

The present study employed various receptor-binding assays to clarify the biochemical characteristics of SM-9018. SM-9018 possessed very high affinity for 5-HT2, D2 and 5-HT1A receptors (Ki = 0.61, 1.4 and 2.9 nM, respectively), and it had moderate affinity for alpha 1 and D1 receptors (Ki = 17 and 41 nM, respectively). However, SM-9018 had only negligible affinity for alpha 2, opiate, glutamate, phencyclidine, benzodiazepine and GABAA receptors. These results suggest that SM-9018 may be a novel antipsychotic agent with binding affinity for 5-HT2 and 5-HT1A receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1982326     DOI: 10.1254/jjp.54.478

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  6 in total

1.  Role of 5-HT(1A) receptors in the modulation of stress-induced lactate metabolism in the medial prefrontal cortex and basolateral amygdala.

Authors:  Takashi Uehara; Tomiki Sumiyoshi; Tadasu Matsuoka; Hiroko Itoh; Masayoshi Kurachi
Journal:  Psychopharmacology (Berl)       Date:  2006-04-05       Impact factor: 4.530

2.  A pharmaco-EEG study on antipsychotic drugs in healthy volunteers.

Authors:  Masafumi Yoshimura; Thomas Koenig; Satoshi Irisawa; Toshiaki Isotani; Keizo Yamada; Mitsuru Kikuchi; Gaku Okugawa; Takami Yagyu; Toshihiko Kinoshita; Werner Strik; Thomas Dierks
Journal:  Psychopharmacology (Berl)       Date:  2007-02-27       Impact factor: 4.530

3.  Experimental analysis of the onset mechanism of TdP reported in an LQT3 patient during pharmacological treatment with serotonin-dopamine antagonists against insomnia and nocturnal delirium.

Authors:  Ryuichi Kambayashi; Mihoko Hagiwara-Nagasawa; Ai Goto; Koki Chiba; Hiroko Izumi-Nakaseko; Atsuhiko T Naito; Akio Matsumoto; Atsushi Sugiyama
Journal:  Heart Vessels       Date:  2019-10-18       Impact factor: 2.037

4.  A novel antipsychotic, perospirone, has antiserotonergic and antidopaminergic effects in human brain: findings from neuroendocrine challenge tests.

Authors:  M Iwakawa; T Terao; A Soya; H Kojima; Y Inoue; N Ueda; R Yoshimura; J Nakamura
Journal:  Psychopharmacology (Berl)       Date:  2004-05-25       Impact factor: 4.530

5.  A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome.

Authors:  Alireza Khalilian; Davoud Ahmadimoghaddam; Shiva Saki; Younes Mohammadi; Maryam Mehrpooya
Journal:  Biopsychosoc Med       Date:  2021-02-03

6.  Perospirone augmentation of escitalopram in the treatment of an adolescent sophophobia (fear of learning) patient.

Authors:  Kensuke Miyazaki
Journal:  Neuropsychopharmacol Rep       Date:  2022-05-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.